Why Environmentalists Should Be Concerned
By Bill McKibben,
WorldWatch
| 06. 30. 2002
July / August 2002
It's not as if environmentalists really need something new to worry about. The planet's temperature is set to rise four or five degrees-every glacial system is already in rapid retreat, and icebergs measured in units of U.S. states (the size of Rhode Island!) are calving off the Antarctic. Species disappear daily; acid rain; and you know the whole damn litany. We could be forgiven for wanting to take a pass on human genetic engineering.
And yet I think it may turn into the single greatest battle environmentalists have ever fought, the one for which the Grand Canyon and the African elephants and Amazon deforestation and Love Canal were preparing us. The real test.
Some of the reasons for thinking so are pragmatic. Changing the human germline is an almost preposterous override of the precautionary principle, the idea that if you don't know something's safe you shouldn't do it. We have rushed with blinding speed through the first phases of the biotechnological revolution-what was experimental a decade ago now grows in half the corn and soybean fields...
Related Articles
By Jason Liebowitz, The New Yorker | 03.06.2026
When Talaya Reid was in high school, in a quiet suburb of Philadelphia, she developed fatigue so severe that she spent afternoons napping instead of going out with friends. She was lethargic at school and her grades suffered, but after...
By Émile P. Torres, Truthdig | 02.26.2026
It’s well known that Jeffrey Epstein was a super-wealthy pedophile with an extraordinary network of powerful friends: tech billionaires, politicians and academics. But few people know that he was also a transhumanist — someone who believes that we should...
By Scott Solomon, The MIT Press Reader | 02.12.2026
Chris Mason is a man in a hurry.
“Sometimes walking from the subway to the lab takes too long, so I’ll start running,” he told me over breakfast at a bistro near his home in Brooklyn on a crisp...
By Zachary Brennan, Endpoints News | 02.23.2026
The FDA is spelling out the details of a new pathway to help speed personalized cell and gene therapies to market for rare diseases.
Monday’s long-awaited draft guidance outlines the agency’s “plausible mechanism” framework, a pathway FDA Commissioner Marty Makary...